In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
Forbes
|
November 3, 2026
This Startup Is Freezing Bone Marrow From Deceased Donors To Save Cancer Patients’ Lives
Ossium Health pioneered a way to cryopreserve bone marrow and completed more than two dozen successful transplants. Now it wants…
For more
Forbes
|
November 2, 2026
Trial To Treatment: BreakThru SCI Reimagines Spinal Cord Injury Care
Last month, BreakThru SCI hosted its first Congressional briefing, “Accelerating Breakthrough Spinal Cord Injury Innovation,” convening more than 70 representatives…
For more
Bloomberg
|
November 2, 2026
Biotech Startups Hunting Drug Discoveries Back Looser SEC Rules
Robert Hoffman was working at a small biotech company when he asked its lead scientist for help with a financial…
For more
New York Post
|
October 22, 2026
I spent 7 years battling the excruciating ‘suicide disease’ — I couldn’t even smile without pain
Natisha “Tish” Long is familiar with what’s considered to be the most agonizing sensations known to humans. Since 2018, an…
For more
Time
|
October 15, 2026
Syndax Revuforj
For decades, patients with some of the most aggressive forms of leukemia had few targeted treatment options. Now, Revuforj is…
For more
Citeline In Vivo
|
October 13, 2026
Ex-FDA Chief Woodcock: Spinal Cord Injury Drugs Need Different Trials
Spinal cord injury needs rare-disease-style flexibility, said Janet Woodcock in an interview. Randomized trials require prespecified, individualized responder indices and…
For more
Healio
|
October 12, 2026
Single rademikibart dose reduces COPD exacerbation-related ED, hospital readmissions
Among patients with COPD and type 2 inflammation at an urgent outpatient visit, the ED or hospital, a single dose…
For more
Parkinson’s News Today
|
October 6, 2026
Use of newly named drug leads to stable motor symptoms in Parkinson’s
Gain Therapeutics’ oral therapy candidate rexaceract, formerly called GT-02287, stabilized motor symptoms in a small group of people with Parkinson’s…
For more
Becker Business Podcast
|
October 1, 2026
Biotech Growth, Capital, and M&A with Dr. Howard Berman of ReAlta Life Sciences
In this episode, Howard Berman, Ph.D., CEO of ReAlta Life Sciences, discusses biotech growth strategy, capital planning, M&A, drug development…
For more
Citeline In Vivo
|
September 28, 2026
Strategic Intent: Boehringer Ingelheim’s Brian Hilberdink on Launching Into the GLP-1 Era
Boehringer Ingelheim’s US Human Pharma president on navigating a major launch cycle, competing in obesity without chasing pounds, and playing…
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
